Cargando…

Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis

BACKGROUND: This study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills (QYDP) in chronic heart failure (CHF) via a long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) axis. Here, the mechanism of action of the lncRNA terminal differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei, Pan, Lihua, Zhang, Yuansheng, Chen, Yuewu, Su, Yangshen, Luo, Ying, Wu, Zengfan, Zheng, Wanling, Cai, Shikang, Liu, Xianxia, Wu, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745534/
https://www.ncbi.nlm.nih.gov/pubmed/36524095
http://dx.doi.org/10.21037/jtd-22-1322
_version_ 1784849173672099840
author Chen, Lei
Pan, Lihua
Zhang, Yuansheng
Chen, Yuewu
Su, Yangshen
Luo, Ying
Wu, Zengfan
Zheng, Wanling
Cai, Shikang
Liu, Xianxia
Wu, Xiaoyan
author_facet Chen, Lei
Pan, Lihua
Zhang, Yuansheng
Chen, Yuewu
Su, Yangshen
Luo, Ying
Wu, Zengfan
Zheng, Wanling
Cai, Shikang
Liu, Xianxia
Wu, Xiaoyan
author_sort Chen, Lei
collection PubMed
description BACKGROUND: This study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills (QYDP) in chronic heart failure (CHF) via a long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) axis. Here, the mechanism of action of the lncRNA terminal differentiation-induced non-coding RNA (TINCR), miR-193b-3p, and RAR-related orphan receptor A (RORA) mRNA was analyzed in an angiotensin (Ang) II-induced H9C2 cardiomyocyte hypertrophy model treated with QYDP. METHODS: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to analyze the gene expression changes of lncRNA, miRNA, and mRNA in H9C2 induced by QYDP on Ang II. The Gene Expression Omnibus (GEO) was used to analyze differentially expressed genes (DEGs) potentially affecting CHF progression. Cell Counting Kit-8 (CCK-8) was used to analyze the effect of QYDP on the proliferation of H9C2, RNA pull-down was used to analyze the binding of lncRNA and miRNA, and dual luciferase was used to analyze the targeting of miRNA and lncRNA or mRNA. RESULTS: Ang II induced TINCR and RORA downregulation, miR-193b-3p upregulation, and hypertrophy in the H9C2 cardiomyocytes, which were alleviated by QYDP. In contrast, TINCR inhibition reversed the effects of QYDP by increasing miR-193b-3p expression and downregulating RORA expression. According to subsequent double luciferase and RNA pull-down experiments, TINCR adsorbed miR-193b-3p by acting as a competitive endogenous RNA sponge and miR-193b-3p directly targeted RORA. Lastly, we showed that the Ang-II-induced inhibition of TINCR and RORA expression and promotion of cardiac hypertrophy were both reversed by a TINCR overexpression plasmid (ov-TINCR), whereas the effects of ov-TINCR were suppressed by a miR-193b-3p mimic. CONCLUSIONS: Administration of QYDP improves Ang II-induced H9C2 cardiomyocyte hypertrophy and increase cell proliferation rate through the TINCR/miR-193b-3p/RORA axis.
format Online
Article
Text
id pubmed-9745534
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-97455342022-12-14 Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis Chen, Lei Pan, Lihua Zhang, Yuansheng Chen, Yuewu Su, Yangshen Luo, Ying Wu, Zengfan Zheng, Wanling Cai, Shikang Liu, Xianxia Wu, Xiaoyan J Thorac Dis Original Article BACKGROUND: This study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills (QYDP) in chronic heart failure (CHF) via a long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) axis. Here, the mechanism of action of the lncRNA terminal differentiation-induced non-coding RNA (TINCR), miR-193b-3p, and RAR-related orphan receptor A (RORA) mRNA was analyzed in an angiotensin (Ang) II-induced H9C2 cardiomyocyte hypertrophy model treated with QYDP. METHODS: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to analyze the gene expression changes of lncRNA, miRNA, and mRNA in H9C2 induced by QYDP on Ang II. The Gene Expression Omnibus (GEO) was used to analyze differentially expressed genes (DEGs) potentially affecting CHF progression. Cell Counting Kit-8 (CCK-8) was used to analyze the effect of QYDP on the proliferation of H9C2, RNA pull-down was used to analyze the binding of lncRNA and miRNA, and dual luciferase was used to analyze the targeting of miRNA and lncRNA or mRNA. RESULTS: Ang II induced TINCR and RORA downregulation, miR-193b-3p upregulation, and hypertrophy in the H9C2 cardiomyocytes, which were alleviated by QYDP. In contrast, TINCR inhibition reversed the effects of QYDP by increasing miR-193b-3p expression and downregulating RORA expression. According to subsequent double luciferase and RNA pull-down experiments, TINCR adsorbed miR-193b-3p by acting as a competitive endogenous RNA sponge and miR-193b-3p directly targeted RORA. Lastly, we showed that the Ang-II-induced inhibition of TINCR and RORA expression and promotion of cardiac hypertrophy were both reversed by a TINCR overexpression plasmid (ov-TINCR), whereas the effects of ov-TINCR were suppressed by a miR-193b-3p mimic. CONCLUSIONS: Administration of QYDP improves Ang II-induced H9C2 cardiomyocyte hypertrophy and increase cell proliferation rate through the TINCR/miR-193b-3p/RORA axis. AME Publishing Company 2022-11 /pmc/articles/PMC9745534/ /pubmed/36524095 http://dx.doi.org/10.21037/jtd-22-1322 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Chen, Lei
Pan, Lihua
Zhang, Yuansheng
Chen, Yuewu
Su, Yangshen
Luo, Ying
Wu, Zengfan
Zheng, Wanling
Cai, Shikang
Liu, Xianxia
Wu, Xiaoyan
Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
title Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
title_full Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
title_fullStr Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
title_full_unstemmed Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
title_short Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
title_sort qishen yiqi dropping pills improve cardiomyocyte hypertrophy via the lncrna tincr/mir-193b-3p/rora axis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745534/
https://www.ncbi.nlm.nih.gov/pubmed/36524095
http://dx.doi.org/10.21037/jtd-22-1322
work_keys_str_mv AT chenlei qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT panlihua qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT zhangyuansheng qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT chenyuewu qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT suyangshen qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT luoying qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT wuzengfan qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT zhengwanling qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT caishikang qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT liuxianxia qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis
AT wuxiaoyan qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis